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The decreasing cost of whole-genome and whole-exome sequencing has resulted in a renaissance for identifying Mendelian disease
mutations, and for the first time it is possible to survey the distribution and characteristics of these mutations in large population
samples. We conducted carrier screening for all autosomal-recessive (AR) mutations known to be present in members of a founder
population and revealed surprisingly high carrier frequencies for many of these mutations. By utilizing the rich demographic, genetic,
and phenotypic data available on these subjects and simulations in the exact pedigree that these individuals belong to, we show that the
majority of mutations were most likely introduced into the population by a single founder and then drifted to the high carrier frequen-
cies observed.We further show that although there is an increased incidence of AR diseases overall, themean carrier burden is likely to be
lower in the Hutterites than in the general population. Finally, on the basis of simulations, we predict the presence of 30 or more undis-
covered recessive mutations among these subjects, and this would at least double the number of AR diseases that have been reported in
this isolated population.Introduction
Founder populations have contributed disproportionally
to the discovery of autosomal-recessive (AR) disease-
causing mutations because affected individuals from these
populations are typically homozygous for founder muta-
tions that reside on relatively long haplotypes, facilitating
mutation discovery by identity by descent (IBD) and
haplotype-sharing methods.1–4 Moreover, despite their
negative impact on fitness, many disease-causing founder
mutations occur at relatively high frequencies in these
populations presumably as a result of the effects of random
genetic drift following the founding bottleneck. Classic
examples of high-frequency founder mutations are those
causing Ellis-van Creveld syndrome (MIM 225500) in the
Amish,5 congenital chloride diarrhea (MIM 214700) in
the Finnish,6,7 Tay-Sachs disease (MIM 272800) in Ashke-
nazi Jews,8 Charlevoix-Saguenay spastic ataxia (MIM
270550) in the Charlevoix-Saguenay-Lac-Saint-Jean region
of Quebec,9 and cystic fibrosis (MIM 219700) in the Hutter-
ites.10 However, in nearly all cases, our understanding of
the impact and fate of founder mutations is based on
identifying homozygous individuals with the disease and
studying these individuals and their close relatives. As a
result, our understanding of the frequency spectrum,
carrier burden, and penetrance of AR disease-causing
founder mutations is limited to those that are observed
in homozygous affected individuals. The recent explosion
of next-generation-sequencing approaches to mutation
discovery facilitates more comprehensive surveys of AR
disease-causing mutations and, for the first time, unbiased
estimates of genetic parameters of deleterious mutations
segregating in founder populations.1Department of Human Genetics, University of Chicago, Chicago, IL 60637,
USA; 3Department of Obstetrics and Gynecology, University of Chicago, Chic
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acterized young founder populations.11–14 To date,>28 AR
diseases have been observed in members of this popula-
tion,13 and causal mutations have been identified in
more than half. We initiated this study to determine the
frequency spectrum of known AR disease-causing muta-
tions in United States Schmeideleut (S-leut) Hutterites
and to identify the AR disease-causing mutations that are
present among the participants in our genetic studies of
complex phenotypes and common diseases.14 Using a
combination of exome sequencing, targeted Sanger
sequencing, and direct genotyping, we identified the
mutations causing three AR conditions in the Hutterites
and determined carrier frequencies and carrier burdens
for 14 mutations associated with 13 AR diseases in
1,644 United States S-leut Hutterites. We report here
remarkably high carrier frequencies of all mutations and
temporal trends that predict increasing incidences of
some of these conditions.Subjects and Methods
Subjects
The Hutterites are an Anabaptist religious group that originated
during the 1500s in the Tyrolean Alps. To escape religious persecu-
tion, the Hutterites lived throughout central and eastern Europe
for the next >300 years. In the 1870s they migrated from Russia
to the United States and settled on three communal farms (called
colonies) in what is now South Dakota. These three colonies
gave rise to the three major Hutterite subdivisions, referred to as
the Schmiedeleut (S-leut), Lehrerleut (L-leut), and Dariusleut
(D-leut). The population has since undergone rapid expansion,
and today >400 Hutterite colonies of all three ‘‘leut’’ are locatedUSA; 2Department of Pediatrics, University of Chicago, Chicago, IL 60637,
ago, IL 60637, USA
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in the north central plain states of the United States and western
provinces of Canada; marriages between leut have been
uncommon for at least the past 90 years. Detailed genealogical
records that extend back to the early 1700s during their tenure
in Russia trace the >40,000 extant members of this founder pop-
ulation to fewer than 90 ancestors.15
Our studies have focused on the United States S-leut Hutterites
residing primarily in South Dakota; some participants are from
colonies in North Dakota and Minnesota. Over the past nearly
30 years, we have conducted genetic studies of fertility,16,17
asthma and other common diseases,14,18 and quantitative pheno-
types.19–21 All of our genetic studies of complex phenotypes have
been population based and have included from ten colonies all
members (six years of age and older) who were home during our
field trips, as well as Hutterite visitors to those colonies on the
days of our field work. Our fertility studies include from an addi-
tional 39 colonies couples in their childbearing years at the time
of enrollment; some of these individuals were enrolled through
the mail. DNA for all subjects was obtained from blood collected
during field trips or from saliva samples collected through the
mail. The final sample for this study includes 1,644 Hutterites,
6–92 years old at the time of our studies, from 56 colonies. These
individuals are related to each other in a 13-generation pedigree
that includes 3,671 individuals, all of whom can be traced to 64
founders.
Written informed consent was obtained from all participants
18 years of age or older and from parents of subjects under 18 years
of age; written assent was obtained from subjects between 6 and
18 years of age. These studies were approved by the institutional
review board at the University of Chicago.
Selection of Disease Mutations
Of the 30 AR diseases described in the Hutterites (Table S1, avail-
able online, adapted from Boycott et al., 2008), mutations were
known for 20 prior to this study. We focused these studies on 14
AR disease-causing mutations that fell into one of the following
three groups: (1) known mutations for diseases that were either
observed or reported to have occurred in study subjects or their
children (n ¼ 5), (2) known disease mutations that were present
in the exome sequences of 25 Hutterites in our sample (n ¼ 6),
or (3) disease mutations that were discovered in our laboratory
during the course of this study (n¼ 3). These 14 disease mutations
are described in Table 1. The eight remaining AR disease-causing
mutations that have been reported in the Hutterites were either
not present or could not be reliably assessed (i.e., insertions and
deletions) in the 25 exomes, and, to our knowledge, the diseases
attributed to those mutations are not present in the families in
our studies.
Exome Sequencing
We selected 25 Hutterites for exome sequencing with the goal of
capturing as much of the genetic variation present in the Hutter-
ites in our sample as possible.33 To achieve that goal, we selected
individuals who were relatively unrelated to each other (mean
pairwise kinship ¼ 0.038 versus 0.041 in the entire sample) and
who had the largest number of genotyped descendants in the
pedigree (median number of genotyped descendants ¼ 31). After
sequencing, we searched among the called variants for previously
reported AR mutations;13,22,25,34 all mutations identified in the
exome sequences were confirmed by Sanger sequencing. Three
(out of five) mutations from group 1 and one (out of three) muta-
tion from group 3 were also present in the 25 exomes. Group 2 wasThe Americcomposed of six additional mutations that were present in the
exomes but for which no individuals affected by these diseases
had been observed or reported in our study participants or their
families.
Mutation Discovery
The third group included three mutations that were identified in
our laboratory in DNA from affected individuals or from obligate
carrier parents. Here, we studied individuals and families with ocu-
locutaneous albinism (OCA1A [MIM 203100]), parents of children
with nonsyndromic deafness (DFNB1A [MIM 220290]), and
parents of a child who died of restrictive dermopathy (RD [MIM
275210]). Sanger sequencing of all five exons of TYR (MIM
606933) was performed in an adult with albinism; variants were
identified by comparison to hg18, and a mutation (RefSeq acces-
sion number NM_000372.4: c.272G>A) resulting in a protein
alteration, p.Cys91Tyr, was identified at a conserved site. This
mutation was then confirmed in DNA from parents whose chil-
dren had albinism and did not participate in our studies
(Figure S1A). The GJB2 (MIM 121011) c.35delG mutation (RefSeq
NM_004004.5) commonly causes nonsyndromic AR deafness in
European populations35 but had not been identified as a cause
of AR deafness in the Hutterites. This mutation was identified
and confirmed by sequencing in both parents of multiple deaf
children (Figure S1B). The ZMPSTE24 (MIM 606480) c.1085dupT
(RefSeq NM_005857.3) mutation causing RD was discovered
simultaneously in our and another laboratory.26 Sequences were
analyzed with 4Peaks (Mekentosj, Amsterdam).
Mutation Screening
We determined the frequency of each of these 14 mutations in
1,644 subjects by direct genotyping (Table S2). In addition, we
used a haplotype-based method to study the SMN1 (MIM
600354) deletion causing spinal muscular atrophy type III (SMA
[MIM 253300]) in 1,415 subjects, as previously described.23 All
genotypes were in Hardy-Weinberg equilibrium according to a
test that adjusts for the Hutterite population structure and
relatedness.36 Mendelian errors were identified by Pedcheck;37
these errors were corrected, but if they could not be unambigu-
ously resolved, the implicated nuclear families were removed
from further analyses. Four couples in our sample were ascertained
because they had children with cystic fibrosis (CF [MIM
219700]);24 these couples and their children were excluded
from population-based estimates of carrier and homozygote
frequencies for CF.
Haplotype Analysis
To determine whether eachmutation occurred on a single founder
haplotype, we used genotypes for 1,415 subjects who were geno-
typed on the Affymetrix 500k, 5.0, or 6.0 SNP arrays. SNPs under-
went quality control (QC) checks as previously described.20 We
included in these studies the 271,486 SNPs that were present on
all three arrays and passed all QC checks.
For the seven mutations that occurred in at least one homozy-
gous individual in our sample, we identified the haplotype
carrying the mutation directly in those individuals. However, to
identify the haplotype(s) shared by carriers of the sevenmutations
that did not occur as homozygous in our sample, we used a
phasing algorithm33 that uses both the known IBD structure of
the population and the Affymetrix genotypes to generate a ‘‘refer-
ence haplotype’’ from a heterozygote that was selected at random.
Then, we used a Perl script to identify the extent to which thean Journal of Human Genetics 91, 608–620, October 5, 2012 609
Table 1. Thirteen AR Diseases and the Corresponding 14 Mutations in the Hutterites
Disease
MIM
Number Chromosome Gene
Mutation
(Common
Name) Mutation (HGVS Name)
Reference
Cluster ID Group
Mutation
Detected in
25 Exomes
Restrictive
dermopathy
275210 1 ZMPSTE24 c.1085dupT NM_005857.3: c.1078dupT rs137854889 3 no
NP_005848.2: p.Cys359_Phe360?fs
Joubert
syndrome
614424 2 TMEM237 R18X NM_001044385.1: c.52C>T rs199469707 2 yes
NP_001037850.1: p.Arg18Ter
Sitosterolemia 210250 2 ABCG8 S107X NM_022437.2: c.320C>G rs137854891 2 yes
NP_071882.1: p.Ser107Ter
Dilated
cardiomyopathy
with ataxia
syndrome
610198 3 DNAJC19 IVS3-1G>C NM_145261.3: c.130-1G>C rs137854888 2 yes
Spinal muscular
atrophy type III
253400 5 SMN1 exon 7 del N/A N/A 1 no
Cystic fibrosis 219700 7 CFTR F508del NM_000492.3: c.1521_1523delCTT rs113993960 1 no
NP_000483.3: p.Ile507_Phe508?
M1101K NM_000492.3: c.3302T>A rs36210737 1 yes
NP_000483.3: p.Met1101Lys
Limb girdle
muscular
dystrophy 2H
254110 9 TRIM32 D487N NM_001099679.1: c.1459G>A rs111033570 2 yes
NP_001093149.1: p.Asp487Asn
Usher syndrome
type 1F
602083 10 PCDH15 c.1471delT NM_001142763.1: c.1101delT rs199469706 2 yes
NP_001136235.1: p.Leu368fs*
Oculocutaneous
albinism type 1A
203100 11 TYR C91Y NM_000372.4: c.272G>A rs137854890 3 yes
NP_000363.1: p.Cys91Tyr
Nonsyndromic
deafness
220290 13 GJB2 c.35delG NM_004004.5: c.35delG rs80338939 3 no
NP_003995.2: p.Gly12Valfs
Bardet-Biedl
syndrome
209900 16 BBS2 IVS3-2A>G NM_031885.3: c.472-2A>G rs137854887 2 yes
Limb girdle
muscular
dystrophy 2I
607155 19 FKRP L276I NM_024301.4: c.826C>A rs28937900 1 yes
NP_077277.1: p.Leu276Ile
Nonsyndromic
mental retardation
614020 19 TECR P182L NM_138501.5: c.545C>T rs199469705 1 yes
NP_612510.1: p.Pro182Leu
This table is ordered by chromosome. Group 1 mutations correspond to diseases that were either previously observed or reported22–24 to have occurred in study
subjects or their children. Group 2 mutations were previously reported in the Hutterites25–32 and were present in the exome sequences of 25 Hutterites. Group 3
mutations were discovered in our laboratory during the course of this study. Both the ‘‘common’’ mutation names, as well as HGVS names, are provided; in some
cases, the coding sequence has been revised since the original mutation publication because the common name is outdated. We use the common names
throughout this manuscript to retain consistency with existing literature on these mutations.reference haplotype was shared among all carriers. The algorithm
starts at the mutation locus in each carrier and scans each consec-
utive SNP on one side of the mutation; it checks for identity by
state (IBS) R 1 with the reference haplotype until it reaches
a SNP for which IBS ¼ 0. The same procedure is used for scanning
SNPs on the other side of the mutation, and the total length of
IBS R 1 sharing is determined by the addition of the segments
on both sides. The algorithm was modified to allow for
n mismatches by tracking the lengths of segments with 0 to
n mismatches on both sides of the mutation and determining
the total extent of sharing by identifying the longest combined
length of segments that contain exactly n total mismatches. We610 The American Journal of Human Genetics 91, 608–620, Octobermanually chose the final value of n for the analysis of each muta-
tion after trying increasing numbers of allowed mismatches and
selecting the n that maximized the number of subjects whose
haplotypes agreed on a particular start or endpoint.
Gene-Dropping Simulations
We performed gene-dropping simulations in the 3,671 person
pedigree to assess the probability that the observed frequencies
of each mutation were consistent with neutral expectations. In
the simulations, a unique mutation was assigned to each founder
and propagated downward through the pedigree—in each of
100,000 iterations—under two different models. In the first5, 2012
model, we assumed that the mutation was neutral (i.e., it had no
effect on fitness) in both heterozygotes and homozygotes
(50% likelihood of transmission regardless of genotype). In the
second model, we assumed that homozygotes for the mutation
had fitness equivalent to zero (homozygosity for the mutation
prevents them from reproducing) and that the fitness of heterozy-
gotes was not affected. Because the pedigree only includes individ-
uals who are ancestral to a genotyped subject in our study, it
follows that all pedigree members must have reproduced and
could not have been homozygous for an AR mutation with fitness
¼ 0. Therefore, when simulating the number of mutations in-
herited by an offspring of two heterozygous parents, we imple-
mented zero fitness by giving the offspring a 0% chance of being
homozygous for the mutation, a 66% chance of being heterozy-
gous, and a 33% chance of being homozygous for the major allele.
This is equivalent to resampling the offspring’s alleles from the
parents until the offspring is not homozygous for the mutation;
this is the method used by Heyer to simulate lethal mutations in
the Saguenay pedigree.38 The first model (neutral) is more reflec-
tive of late-onset diseases (e.g., limb girdle muscular dystrophy
2H [LGMD2H (MIM 254110)]) or those that have an early onset
and that have limited or no effect on reproductive fitness
(e.g., oculocutaneous albinism or sitosterolemia [STSL (MIM
210250)]), whereas the latter model (lethal or zero fitness) is
more reflective of early-onset diseases that are either lethal prior
to reproduction (e.g., RD) or limit or preclude reproduction in
surviving adults (e.g., CF [MIM 219700]).
To determine the probability that a mutation present in a single
Hutterite founder would reach a given carrier frequency, we calcu-
lated the proportion of iterations in which the founder’s mutation
reached the frequency of the mutation observed in the study
sample.We used a regression-based test designed for large complex
pedigrees (general two-allele model)39 to test for an association
between carrier status and fertility in the Hutterites. The fertility
phenotypes, family size, and birth rate have been described else-
where.40 These analyses were performed with and without couples
in which both individuals were carriers of the same mutation in
case some parents altered their reproductive plans after the diag-
nosis of a child with the corresponding disease.
Carrier Burden
We defined carrier burden as the number of AR disease-causing
mutations per genome. This was assessed in 686 individuals who
had a nonmissing genotype at all 14 mutations studied. In
addition, we assessed their expectedmean carrier burden for simu-
lated founder mutations. Using the same gene-dropping simula-
tions described above, we assigned all of the founders one,
two, three, or five unique unlinked mutations each and dropped
those mutations through the pedigree. We then determined the
total number of founder alleles carried by each individual. To
increase simulation efficiency, we assigned the same number of
mutations (x) to each founder, although this is mathematically
equivalent to treating the number of mutations per founder as
independent and identically distributed random variables with
mean x (in other words, giving each founder exactly three muta-
tions will produce equivalent results to randomly picking each
founder’s number of mutations from a distribution with a mean
of 3). Finally, we calculated the 95% confidence intervals for the
mean carrier burden and expected number of surviving mutations
by taking themiddle 95% of values. In all cases, 100,000 trials were
performed. Code for all gene-dropping and carrier-burden simula-
tions is available online.The AmericResults
Carrier Frequencies
Seven of the 14mutations present in the Hutterites are also
present in other populations, and four of these are the
most common for each disease in Europeans—they are
a SMN1 (MIM 600354) deletion causing SMA, p.Phe508del
(RefSeq NM_000492.3: c.1521_1523delCTT) causing
CF, c.35delG causing DFNB1A, and p.Leu276Ile (RefSeq
NM_024301.4: c.826C>A) causing limb girdle muscular
dystrophy 2I (LGMD2I [MIM 607155]). In contrast,
TRIM32 p.Asp487Asn (RefSeq NM_001099679.1:
c.1459G>A) and ZMPSTE24 c.1085dupT are rare outside
the Hutterites—there are only a few case reports world-
wide of each mutation in non-Hutterites—and CFTR
p.Met1101Lys (RefSeq NM_000492.3: c.3302T>A) has
only been reported in one individual with CF from the
South Tyrol,41 the home of some of the Hutterite founders.
The remaining seven mutations have not been reported
outside of the Hutterites (these mutations are referred to
as ‘‘private’’ mutations in Table 2).
The frequencies of the 14 mutations varied greatly;
carrier frequencies ranged from 1 in 6.5 for TRIM32
(MIM 602290) p.Asp487Asn, which causes LGMD2H
(MIM 254110), to 1 in 45 for CFTR p.Phe508del (RefSeq
NM_000492.3: c.1521_1523delCTT), which causes CF
(Table 2). We were aware of individuals with oculocutane-
ous albinism type 1A (OCA1A) (n ¼ 3), SMA (n ¼ 1),
LGMD2I (n ¼ 3), nonsyndromic mental retardation
(NSMR [MIM 614020]) (n ¼ 5), and CF (n ¼ 6) in our
sample, and each was homozygous for the expected
disease mutation. However, 14 individuals were homozy-
gous for three AR mutations but were unaware of their
status: nine individuals (ages 10–42 years) were homozy-
gous for the LGMD2H-causing mutation, four individuals
(one pair of teenage siblings and one pair of adult siblings)
were homozygous for the STSL mutation, and one
adult was homozygous for the SMA deletion mutation as
previously reported.23 On a subsequent exam, all four of
the subjects with STSL-causing mutations had elevated
sitosterol levels (4.29–19.0 mg/100 ml), which is diag-
nostic for STSL (D.J. Waggoner, personal observation).
The adult woman who was homozygous for the SMA-
causing deletion was 41 years old and asymptomatic at
the time of our study; she died of cancer at age 50 without
any symptoms related to SMA according to her close
relatives. No additional information is available for the
other subjects.
Haplotype Analyses
A priori, we expected that all privatemutations would have
been introduced by a single founder and that each of those
mutations would be present on a single haplotype
background. Although the expectation is less clear for
mutations that have been observed in non-Hutterite pop-
ulations, it would not be surprising if some of these muta-
tions (e.g., the SMN1 deletion or GJB2 c.35delG) werean Journal of Human Genetics 91, 608–620, October 5, 2012 611
Table 2. Results of Carrier Screening for 14 AR Mutations in 1,644 Hutterites from South Dakota
Disease Gene Mutation
Number of
Heterozygotes
Number of
Homozygotes
Number
Screened
Carrier Frequency
in Hutterites
Carrier Frequency
in Other Populations
Limb girdle muscular
dystrophy 2H
TRIM32 p.Asp487Asn 228 9 1,493 0.153 (1 in 6.5) unknown (only two
non-Hutterite cases
reported42)
Oculocutaneous
albinism type 1A
TYR p.Cys91Tyr 180 3 1,281 0.141 (1 in 7) private mutation
Spinal muscular
atrophy type III
SMN1 exon 7 del 179 2 1,415 0.127 (1 in 8) 1 in 3543
Limb girdle muscular
dystrophy 2I
FKRP p.Leu276Ile 121 3 1,127 0.107 (1 in 9.5) 1 in 30044
Sitosterolemia ABCG8 p.Ser107Ter 127 4 1,515 0.084 (1 in 12) private mutation
Joubert syndrome TMEM237 p.Arg18Ter 122 0 1,520 0.080 (1 in 12.5) private mutation
Cystic fibrosis CFTR p.Met1101Lys 108 6 1,473 0.073 (1 in 13.5) unknown (only one
non-Hutterite case
reported41)
Nonsyndromic mental
retardation
TECR p.Pro182Leu 103 5 1,496 0.069 (1 in 14.5) private mutation
Restrictive dermopathy ZMPSTE24 c.1085dupT 87 0 1,361 0.064 (1 in 15.5) unknown (<60 cases
worldwide45)
Nonsyndromic deafness GJB2 c.35delG 54 0 1,510 0.036 (1 in 28) 1 in 4035
Dilated cardiomyopathy
with ataxia syndrome
DNAJC19 IVS3-1G>C 42 0 1,504 0.028 (1 in 36) private mutation
Bardet-Biedl syndrome BBS2 IVS3-2A>G 42 0 1,518 0.028 (1 in 36) private mutation
Usher syndrome
type 1F
PCDH15 c.1471delT 38 0 1,524 0.025 (1 in 40) private mutation
Cystic fibrosis CFTR p.Phe508del 32 0 1,482 0.022 (1 in 45.5) 1 in 3046
This table is ordered by carrier frequency. The combined carrier frequency for cystic fibrosis (c.1521_1523delCTT þ c.3302T>A) is 0.093 (1 in 11). We use
common mutation names to retain consistency with the existing literature.introduced by more than one founder and present on
more than one haplotype background. To address this,
we characterized the extent of haplotype sharing around
the mutations in homozygotes, if available, and in hetero-
zygotes if no homozygotes were present in our sample. The
lengths of the shared haplotypes around each mutation
and the number of SNPs defining each haplotype are
described in Table 3.
Zielenski et al.10 previously identified two CFTR (MIM
602421) p.Met1101Lys-bearing Hutterite haplotypes—
a common haplotype (b) and a rare haplotype (c) that
was only present in a single family—and hypothesized
that haplotype cwas derived from b by a single recombina-
tion proximal to p.Met1101Lys (RefSeq NM_000492.3:
c.3302T>A). Five p.Met1101Lys homozygotes in our
sample had two copies of the common b haplotype across
~8 Mb (659 SNPs) surrounding CFTR, and examination of
98 p.Met1101Lys carriers revealed that all 98 also carried
the b haplotype. We identified a sixth p.Met1101Lys
homozygote who carried this alteration on haplotypes
b and c. However, haplotype analysis revealed that the
c haplotype differs from the b haplotype at multiple SNPs
both proximal and distal to p.Met1101Lys (Figure S2).
Therefore, two recombinations would be required for612 The American Journal of Human Genetics 91, 608–620, Octoberexplaining the origin of p.Met1101Lys -bearing haplotypes
c from b. Alternatively, two founders might have intro-
duced p.Met1101Lys into the Hutterites on different
haplotype backgrounds.
The remaining 13 mutations are present on a single
extended haplotype, suggesting that one founder intro-
duced each of these mutations into the population. This
is consistent with previous studies of BBS2 (MIM 606151)
IVS3-2A>G (RefSeq NM_031885.3: c.472-2A>G),27 TECR
(MIM 610057) p.Pro182Leu (RefSeq NM_138501.5:
c.545C>T),22DNAJC19 (MIM 608977) IVS3-1G>C (RefSeq
NM_145261.3: c.130-1G>C),28 ZMPSTE24 c.1085dupT,26
FKRP p.Leu276Ile,44 TRIM32 p.Asp487Asn,29 and the
SMN1 deletion.23 The ZMPSTE24 c.1085dupT mutation
was present on a relatively long (>1 Mb) haplotype in the
majority of carriers, and four other carriers shared <1 Mb
of the large haplotype. These carriers were members of
a single family in which amother and three of her children
were heterozygous for ZMPSTE24 c.1085dupT but only
had ~0.6 Mb of the long shared haplotype; the mother’s
brother carried the alteration on the long haplotype
(Figure S3). In this family, it is likely that the mother
inherited c.1085dupT on a recombinant haplotype and
passed it on to her offspring.5, 2012
Table 3. Analysis of Shared Haplotypes Bearing AR Mutations
Mutation (Gene)
Heterozygotes Homozygotes
n
Kinship Coefficient
(Mean [Min, Max])
Consensus
Length
(bp)
Consensus
Length
(SNPs) n
Kinship Coefficient
(Mean [Min, Max])
Consensus
Length
(bp)
Consensus
Length
(SNPs)
Mismatches
Allowed
p.Asp487Asn (TRIM32) 189 0.049 (0.01, 0.30) 449,953 90 8 0.054 (0.02, 0.29) 2,553,354 417 2
p.Cys91Tyr (TYR) 155 0.049 (0.01, 0.30) 4,086,749 416 3 0.046 (0.03, 0.07) 15,476,024 1812 1
exon 7 del (SMN1) 177 0.053 (0.01, 0.29) 2,834,415 84 2 0.027 (0.03, 0.03) 9,990,562 917 3
p.Leu276Ile (FKRP) 116 0.051 (0.01, 0.29) 1,433,672 48 3 0.079 (0.04, 0.16) 8,695,515 444 2
p.Ser107Ter (ABCG8) 117 0.057 (0.01, 0.29) 2,120,092 290 4 0.134 (0.07, 0.28) 9,041,651 500 2
p.Arg18Ter (TMEM237) 106 0.052 (0.01, 0.30) 3,666,069 336 0    2
p.Met1101Lys (CFTR)a 98 0.055 (0.02, 0.29) 3,011,533 229 5 0.131 (0.04, 0.28) 8,221,623 659 2
p.Pro182Leu (TECR) 93 0.058 (0.02, 0.29) 1,941,199 138 5 0.286 (0.29, 0.29) 2,455,513 196 2
c.1085dupT
(ZMPSTE24)
85 0.066 (0.02, 0.29) 692,209 63 0    2
c.35delG (GJB2) 46 0.058 (0.02, 0.30) 1,995,634b 162 0    2
IVS3-1G>C (DNAJC19) 41 0.127 (0.02, 0.29) 2,073,507 122 0    2
IVS3-2A>G (BBS2) 42 0.081 (0.01, 0.28) 2,118,302 230 0    2
c.1471delT (PCDH15) 31 0.082 (0.03, 0.29) 6,681,213 829 0    3
p.Phe508del (CFTR) 27 0.077 (0.02, 0.30) 4,260,744 296 0    2
This table is ordered by carrier frequency. We use commonmutation names to retain consistency with the existing literature. The following abbreviations are used:
min, minimum; and max, maximum.
aThe c.3302T>A mutation is present on two Hutterite haplotypes,10 one of which is rare. Our sample included one c.3302T>A homozygote who was
heterozygous for the two haplotypes. Because there were no other c.3302T>A carriers on this haplotype background, the consensus data are presented for
the common haplotype only.
bThe GJB2 c.35delG haplotype might be up to ~0.25 Mb longer than reported here because the proximal end of the haplotype is near the centromere, and no
SNPs within that region were genotyped in our sample.Gene-Dropping Simulations
To characterize the expected frequencies of the founder
mutations causing AR diseases, we performed gene-drop-
ping simulations to generate null distributions ofmutation
frequencies given the exact structure of the Hutterite pedi-
gree. This was performed under two models, one in which
the homozygotes for the mutation have zero fitness (i.e.,
do not reproduce) and one in which the mutation is
neutral. As expected, the founders with the most descen-
dants in our study had the greatest variance in simulated
carrier frequencies such that in one trial (1/100,000) the
carrier frequency for the founder’s mutation was as high
as 40%, whereas in nearly half of the trials (42,209/
100,000) the same mutation went to extinction in early
generations (Figure 1A). Similarly, we observed a clear
and unsurprising correlation between the number of indi-
viduals descended from each founder in the current popu-
lation and the expected carrier frequency for each
founder’s mutation. For example, mutations introduced
by any one of six founders (three founder couples) who
were ancestral to all or nearly all members of the sample
had between 50% and 74% probability of reaching carrier
frequencies of 5% or greater and a R10% probability of
reaching carrier frequencies of 10% or greater. In fact, if
one assumes that the number of unique (rare) variantsThe Americcarried by each of the 64 Hutterite founders was drawn
from the same distribution, those six founders are ex-
pected to collectively account for 15.4% of the variants
currently segregating in the sample.
Given the evidence suggesting that 13 out of the 14
mutations were each introduced by a single founder on
a single haplotype, we next asked how often this would
result in mutations reaching frequencies as high as those
observed in the Hutterites. For each mutation, we limited
the potential contributing founders to those who are
ancestral to all carriers of each mutation and determined
the probability of reaching a target frequency under two
models, one in which the homozygotes for the mutation
have zero fitness and one in which the mutation is neutral.
Diseases in which homozygotes do not reproduce are best
modeled in the first scenario, whereas diseases with late
ages of onset or reduced penetrance are modeled better
in the second scenario. For each mutation, the probability
of reaching the current carrier frequency under the more
appropriate model is indicated in Table 4. Most of the
mutations except the three most common (TRIM32
p.Asp487Asn, TYR p.Cys19Tyr, and the SMN1 deletion)
had R5% probability of reaching the current carrier
frequency by drift alone. To determine whether a heterozy-
gote fertility advantage could have contributed to the highan Journal of Human Genetics 91, 608–620, October 5, 2012 613
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Figure 1. Results of Gene-Dropping Simulations
(A–C) Simulated carrier frequency in the current population for each unique founder mutation. Box plots show the distribution
(first quartile, median, and third quartile; dashed lines show minimum and maximum) of frequencies that each founder mutation
reached in 100,000 trials under two models. The box plots are ordered in pairs from left to right by the number of descendants (shown
along x axis beneath box plots) in the study sample from each founder. The first box plot in each pair shows the simulated frequencies
under a neutral model, and the second box plot shows the simulated frequencies under a zero fitness (lethal) model. In the current
population, the expected percentage of variants that are attributable to a given founder is shown above the box plots. In (B) and (C),
each line represents the simulated frequency of (B) heterozygous carriers and (C) homozygotes for a neutral founder mutation in
25 year birth cohorts. For many founder mutations, the frequency of homozygotes increases over time, whereas there is no such pattern
observed for the frequency of carriers.
(D) Inbreeding coefficient by birth cohorts. The increase in consanguinity corresponds to the increase in the frequency of
homozygotes in (C).carrier frequencies of these three common mutations,
we tested whether carrier status was associated with
increased fertility, as measured by number of offspring,
parents’ age at the birth of their last child, and birth
rate.40 None of the mutations were associated with fertility
in this sample (pR 0.19 for all phenotypes), although the
numbers of carriers were relatively small (fertility pheno-
types were available for %45 carriers for any single muta-
tion) and provided limited power for detecting small
effects. This lack of association was robust to the inclusion
or exclusion of couples in which both partners carried the
same mutation.
Temporal Changes in Carrier Frequency
From the gene-dropping simulations, we also estimated
genotype frequencies for each unique founder mutation
by birth cohort. Although the carrier frequencies changed
little over successive generations (Figure 1B), the frequency
of homozygotes for most founder mutations increased in
each generation (Figure 1C) most likely as a result of the614 The American Journal of Human Genetics 91, 608–620, Octoberincreasing consanguinity in the population (Figure 1D).
Consistent with our simulations, there was no obvious
pattern of change in carrier frequencies for the 14 disease
mutations in successive 25 year birth cohorts in this
sample (Figure 2A), but the frequency of couples in which
both parents are carriers (and at risk for having affected
children) (Figure 2B) and the frequency of homozygotes
(Figure 2C) have been increasing over time.
Carrier Burden
The 686 individuals with nonmissing genotypes at all
14 disease mutations had a mean carrier burden of 1.096
mutations—67% of them carried at least one mutation,
and some individuals carried up to five of mutations
(Figure 3). These data are consistent with the expectation
that carrier burden follows a Poisson distribution
(p ¼ 0.28 that the data is not Poisson distributed). In addi-
tion, we decomposed the total mean carrier burden into
the mean carrier burden of neutral and nearly neutral
versus lethal (zero fitness) mutations and found that the5, 2012
Table 4. Results of Gene-Dropping Simulations
Disease Gene Mutation
Carrier
Frequency
in Hutterites
Number of
Founders
Ancestral to
All Carriers
Most
Likely
Model
Probability of
Reaching Frequency
under Neutral Model
(95% CI)
Probability of
Reaching Frequency
under 0 Fitness Model
(95% CI)
Limb girdle
muscular dystrophy 2H
TRIM32 p.Asp487Asn 0.153 12 1 0.0318 (3.1 3 104) 0.0188 (2.4 3 104)
Oculocutaneous
albinism type 1A
TYR p.Cys91Tyr 0.141 15 1 0.0382 (3.1 3 104) 0.0256 (2.5 3 104)
Spinal muscular
atrophy Type III
SMN1 exon 7 del 0.127 13 0 0.0574 (4.0 3 104) 0.0427 (3.5 3 104)
Limb girdle muscular
dystrophy 2I
FKRP p.Leu276Ile 0.107 17 1 0.0711 (3.9 3 104) 0.0575 (3.5 3 104)
Sitosterolemia ABCG8 p.Ser107Ter 0.084 16 1 0.1256 (5.1 3 104) 0.1110 (4.9 3 104)
Joubert syndrome TMEM237 p.Arg18Ter 0.080 17 0 0.1405 (5.2 3 104) 0.1261 (5.0 3 104)
Cystic fibrosis CFTR p.Met1101Lys 0.073 18 0 0.1198 (4.7 3 104) 0.1089 (4.6 3 104)
Nonsyndromic mental
retardation
TECR p.Pro182Leu 0.069 18 0 0.1631 (5.4 3 104) 0.1513 (5.2 3 104)
Restrictive dermopathy ZMPSTE24 c.1085dupT 0.064 26 0 0.1518 (4.4 3 104) 0.1432 (4.3 3 104)
Nonsyndromic deafness GJB2 c.35delG 0.036 27 1 0.2607 (5.2 3 104) 0.2546 (5.2 3 104)
Dilated cardiomyopathy
with ataxia syndrome
DNAJC19 IVS3-1G>C 0.029 28 0 0.2909 (5.3 3 104) 0.2862 (5.3 3 104)
Bardet-Biedl syndrome BBS2 IVS3-2A>G 0.028 22 0 0.3214 (6.2 3 104) 0.3164 (6.2 3 104)
Usher syndrome type 1F PCDH15 c.1471delT 0.025 20 0 0.3221 (6.5 3 104) 0.3175 (6.5 3 104)
Cystic fibrosis CFTR p.Phe508del 0.022 30 0 0.3437 (5.4 3 104) 0.3399 (5.4 3 104)
This table is ordered by carrier frequency. The probability that each of the 14 AR mutations reached the carrier frequency observed in our study sample is shown in
the last two columns. Probabilities are given for two extreme models: a neutral model and a zero fitness (lethal) model. The more appropriate model based
on clinical phenotypes is indicated in column 4 (1 ¼ neutral model; 0 ¼ lethal model). We use common mutation names to retain consistency with the existing
literature. The following abbreviation is used: CI, confidence interval.mean carrier burden of lethal and neutral mutations (not
shown) is approximately equal (0.55 for lethal versus
0.54 for neutral mutations per individual). Finally, we
‘‘seeded’’ each founder with a set number of mutations
and performed gene-dropping simulations to generate
expectations for the distribution of carrier burden. Mean
carrier burden for neutral mutations remained constant
from the founders to the current generation, as expected.
In contrast, in simulations assuming that mutations are
homozygous lethal, the mean carrier burden in the study
subjects decreased to 92% of the mean carrier burden in
the founders (see Table 5, lines correspond to onemutation
per founder).
Because we did not genotype all mutations causing AR
diseases (Table S1) in the Hutterites, the true mean carrier
burden must certainly be higher than 1.096 mutations
per individual. We calculated expectations for the true
mean carrier burden (Table 5) by assigning different
numbers of mutations to each founder and dropping those
mutations through the pedigree. If we assume that, on
average, each of the 64 Hutterite founders carried three
unique AR mutations,47 our simulations show that 73
mutations (38% of founder mutations) are expected to still
be present in our study subjects; this corresponds to an ex-
pected mean carrier burden between 2.76 and 3 mutationsThe Americper Hutterite (depending on the relative proportions of
lethal and neutral mutations).
Because some of the 64 Hutterite founders were most
likely related,48 we also considered the possibility that
some mutations might have been introduced into the
population by more than one founder and might thereby
have resulted in a higher initial carrier frequency. How-
ever, the simulations indicate that under the neutral
model, the expected mean burden in our study subjects
will always be equivalent to the mean burden in the
founders, regardless of the initial carrier frequency.
However, under the lethal mutation model, as compared
to the model shown in Table 5, the expected mean burden
in the current population will be even lower than the
initial mean burden in the founders because mutations
occurring at a higher frequency in the founders will be
eliminated at a faster rate.49Discussion
Influence of Drift on Mutations in an Isolated
Population
This study provides empiric illustration of the powerful
effects of drift on rare recessive mutations in a founderan Journal of Human Genetics 91, 608–620, October 5, 2012 615
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Figure 2. Observed Frequencies of Carriers, Carrier Couples, and Homozygotes over Time for 14 Disease Mutations
Four CF carrier couples were excluded because they were previously ascertained for having children with CF.24
(A) Heterozygote frequencies in 25 year birth cohorts. The cohorts born before 1925 and after 2000 were excluded because of small
sample sizes (n < 60). The black dashed line shows the cumulative carrier frequency for all 14 mutations.
(B) Frequency of carrier couples. Both partners of one couple were carriers of DNAJC19 IVS3-1G>C and TECR p.Pro182Leu and are
included twice in this figure.
(C) Frequency of homozygotes born to each couple in (B). There are no homozygotes shown among the children of theR2000marriage
cohort because our study included children who were 6 years of age or older at the time of our last study in 2006–2009. Although we
are aware that these families include children homozygous for SMA (n ¼ 4) and CF (n ¼ 2), we did not include them because we do
not know the status of children born to all carrier couples. In addition, because infants homozygous for ZMPSTE24 c.1085dupT, causing
RD, die within a few days of birth, homozygotes for this mutation would not have been included in our studies. However, family-history
interviews with carrier couples and acquisition of medical records allowed us to identify homozygous children, who are included in
this figure.population. On one hand, the founder effect reduces the
amount of variation present among the founders, and drift
results in the further loss of the majority of rare variants
from those founders during the first few generations of
the pedigree. These phenomena are illustrated by our
simulations and the observation that many ‘‘common’’
Mendelian disease mutations, such as those causing
phenylketonuria, hemophilias, Fragile X Syndrome, and
Duchenne muscular dystrophy, have not been observed
in the Hutterites. On the other hand, the surviving
variants can drift to high frequencies over subsequent
generations. High-frequency disease-causing mutations
in founder populations have been the subject of many
investigations into whether the high carrier frequencies
might be evidence of balancing (overdominant) selec-
tion.38,50–53 For example, allele-dropping simulations in
the Saguenay population also show that after the introduc-
tion of an AR mutation by just a single founder, the
stochastic effects of drift can generate high carrier frequen-
cies and that the lethality of a mutation has relatively little
effect on the frequencies it reaches in later generations.38616 The American Journal of Human Genetics 91, 608–620, OctoberSimilarly, although we cannot exclude the possibility of
selective advantage in carriers of the mutations studied
here, we show that the high carrier frequencies for 11
out of 14 mutations in this study are consistent with
expectations from a founder effect followed by population
expansion. Furthermore, we failed to find a fertility advan-
tage for carriers of the three remaining mutations. In fact,
the probabilities that the mutations could have reached
the current carrier frequencies (Table 4) are most likely
underestimates because our simulations assumed that
each mutation was present in only one founder. Instead,
the mutations might have been segregating in the Hutter-
ites’ ancestral populations, and some of the founders
might have been related;48 hence, multiple founders could
have introduced the same mutation on a single haplotype.
This possibility is supported by the fact that four of the
mutations (TRIM32 p.Asp487Asn, FKRP p.Leu276Ile,
CFTR p.Met1101Lys, and ZMPSTE24 c.1085dupT) we
studied are known to be present on the same haplotype
in the Hutterites and in populations from which some of
the Hutterite founders might have originated.26,41,42,445, 2012
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Figure 3. Distribution of Carrier Burden in 686 Subjects Who
Were Genotyped for All 14 Mutations in This Study
The mean carrier burden (defined as the number of mutations
per individual) is 1.096 mutations. Black dots represent the theo-
retical expected number of subjects in each bin of mutations
with a Poisson distribution with l ¼ 1.096.We hypothesize that as more human genomes are
sequenced, many mutations currently thought to be
private to the Hutterites will be discovered at low frequen-
cies in other European populations.
Consequences of Short Consensus Haplotypes
on Disease Mapping
The possibility that some undiscovered AR mutations in
the Hutterites might be present on haplotypes that have
very short regions of overlap could confound mapping
efforts that utilize homozygosity and linkage analysis. As
an example worst-case scenario, some carriers of TRIM32Table 5. Results of Simulations of Carrier Burden
Mean Mutations
per Founder
Total Founder
Mutations
Expected Mean
in Study Samp
Neutral Fitness of Homozygotes
1 64 1.00 [0.63, 1.42
2 128 2.00 [1.47, 2.58
3 192 3.00 [2.34, 3.71
5 320 5.00 [4.14, 5.91
Lethal Fitness of Homozygotes
1 64 0.92 [0.60, 1.28
2 128 1.84 [1.37, 2.35
3 192 2.77 [2.18, 3.38
5 320 4.61 [3.86, 5.40
The expected mean carrier burden in the study sample is shown and assumes tha
(column 1) into the population. Expected mean carrier burden for independent
burden for lethal mutations will be reduced from the mean carrier burden in the
accuracy and might appear as integers because of extremely small errors in our s
is 1.000059). The following abbreviation is used: CI, confidence interval.
The Americp.Asp487Asn only share a ~449 kb segment, so an affected
child born to two such carriers would carry the mutation
within an extremely short run of homozygosity. If the
child were genotyped on the Illumina HumanCytoSNP-
12 array (median intermarker distance of 6.2 kb), which
is often used in Mendelian disease mapping, the child
would have as few as 72 consecutive homozygous SNPs
around the disease locus. Although the literature contains
numerous examples of successful homozygosity-mapping
efforts, many more mutations might have thus far eluded
identification by being carried on short haplotypes.Carrier Burden in a Founder Population
Early theoretical studies of lethal mutation burden in
humans estimated that each person is a carrier of 3–5 reces-
sive lethal mutations,54–56 whereas a recent study of 448
disease mutations in 104 individuals from outbred popula-
tions reported a mean carrier burden of 2.8 per genome.47
Although we cannot compare these values against the
mean carrier burden in this study because we only studied
14 mutations, our simulations of carrier burden demon-
strate that the Hutterites are expected to carry fewer AR
disease-causing mutations per individual than what is re-
ported for individuals from large, outbred populations.
Although it seems counterintuitive that the Hutterites
have the same or even less of a carrier burden per indi-
vidual in light of the relatively high incidence of AR disease
in the Hutterites, the fact that each Hutterite is more likely
tomarry someonewho carries the samemutation results in
a higher incidence of homozygous children, albeit for a
smaller number of diseases. This scenario will also result
in recessive mutations being removed from the population
at a greater rate than in an outbred population.49 This was
evidenced by the simulation showing an 8% decrease inCarrier Burden
le [95% CI]
Expected Number of Mutations
Surviving in Study Sample [95% CI]
] 24.4 [19, 30]
] 48.8 [41, 57]
] 73.1 [63, 83]
] 121.9 [109, 135]
] 24.4 [19, 30]
] 48.7 [41, 57]
] 73.0 [63, 83]
] 121.7 [109, 135]
t each of the 64 founders introduced a specified number of unique mutations
ly segregating neutral mutations will not change, but expected mean carrier
founders. Expected mean carrier burden is reported to two decimal places of
imulations (e.g., the expected mean burden given one mutation per founder
an Journal of Human Genetics 91, 608–620, October 5, 2012 617
carrier burden for lethal recessive mutation over just 13
generations.
Unexpectedly, we found that even if the 64 Hutterite
founders carried only three unique AR mutations each,
73 mutations (95% confidence interval ¼ 61–85) are
expected to be segregating in the population today;
this leaves a large (R2.53) discrepancy between the
numbers of expected and observed AR diseases and muta-
tions in the Hutterites. Some of these as yet undiscovered
diseases might be mild, have onset late in life, or have
variable penetrance or expressivity: one of the TRIM32
p.Asp487Asn homozygotes is 43 years old and is currently
asymptomatic, and we have also previously reported an
asymptomatic SMA homozygote. Other mutations are ex-
pected to be sufficiently rare that homozygosity for these
mutations might not yet have occurred. An alternative
(or complementary) explanation is that because some of
the founders were most likely related, the same mutation
might have been introduced into the population by
multiple founders. The truth probably lies between these
extremes—there are perhaps 30 or more disease mutations
yet to be discovered in this well-studied population.Supplemental Data
Supplemental Data include three figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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